{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:51:11Z","timestamp":1788889871898,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Waters Corporation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jpba.2019.04.049","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T11:24:39Z","timestamp":1559129079000},"page":"151-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography"],"prefix":"10.1016","volume":"174","author":[{"given":"Sebastian","family":"Schmidtsdorff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander H.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2019.04.049_bib0005","unstructured":"FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm613916.htm (Last accessed: 01. April 2019)."},{"key":"10.1016\/j.jpba.2019.04.049_bib0010","unstructured":"Committee for Medicinal Products for Human Use (16. July 2018) CHMP List of questions - To be addressed by the API manufacturers for valsartan-containing medicinal products (Procedure number: EMEA\/H\/A-31\/1471). European Medicines Agency - London, United Kingdom https:\/\/wwwemaeuropaeu\/en\/documents\/referral\/valsartan-article-31-referral-chmp-list-questions-be-addressed-api-manufacturers-valsartan_enpdf."},{"key":"10.1016\/j.jpba.2019.04.049_bib0015","first-page":"50","article-title":"Noch mehr Nitrosamine - NDMA, NDEA, NDIPA - wie kommen die Verunreinigungen in die Sartane?","volume":"159","author":"Buschmann","year":"2019","journal-title":"In: Deutsche Apotheker Zeitung"},{"key":"10.1016\/j.jpba.2019.04.049_bib0020","series-title":"FDA Provides Update on Its Ongoing Investigation Into Valsartan Products; and Reports on the Finding of an Additional Impurity Identified in One Firm\u2019s Already Recalled Products","author":"U.S. Food & Drug Administration","year":"2018"},{"key":"10.1016\/j.jpba.2019.04.049_bib0025","first-page":"2898","article-title":"Valsartan: ZL findet NDMA in Tabletten","volume":"158","author":"Abdel-Tawab","year":"2018","journal-title":"Pharm. (1856)"},{"key":"10.1016\/j.jpba.2019.04.049_bib0030","series-title":"EU Authorities Take Further Action in Ongoing Review of Sartans: Zheijiang Huahai Placed Under Increased Supervision; Aurobindo Pharma Stopped From Supplying Irbesartan to the EU","author":"EMA\/703416\/2018","year":"2018"},{"key":"10.1016\/j.jpba.2019.04.049_bib0035","volume":"vol. 17","author":"International Agency for Research on Cancer","year":"1978"},{"key":"10.1016\/j.jpba.2019.04.049_bib0040","series-title":"N-Nitrosodimethylamine, Concise International Chemical Assessment Document 38","author":"World Health Organization","year":"2002"},{"key":"10.1016\/j.jpba.2019.04.049_bib0045","series-title":"Technical Fact Sheet - N-Nitrosodimethylamine","author":"U.S. Environmental Protection Agency, Federal Facilities Restoration and Reuse Office","year":"2017"},{"key":"10.1016\/j.jpba.2019.04.049_bib0050","series-title":"Update on Review of Recalled Valsartan Medicines","author":"EMA\/526031\/2018","year":"2018"},{"key":"10.1016\/j.jpba.2019.04.049_bib0055","series-title":"GC\/MS Headspace Method for Detection of NDMA in Valsartan Drug Substance","author":"U.S. Food & Drug Administration, Center for Drug Evaluation and Research","year":"2018"},{"key":"10.1016\/j.jpba.2019.04.049_bib0060","series-title":"OMCLs Release Three Methods for Determination of NDMA in Sartans","author":"European network of OMCLs","year":"2018"},{"key":"10.1016\/j.jpba.2019.04.049_bib0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jpba.2015.03.007","article-title":"Supercritical fluid chromatography in pharmaceutical analysis","volume":"113","author":"Desfontaine","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.04.049_bib0070","series-title":"Supercritical Fluid Chromatography","article-title":"Theory and principles of supercritical fluid chromatography","author":"Bartle","year":"1988"},{"key":"10.1016\/j.jpba.2019.04.049_bib0075","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chroma.2012.07.043","article-title":"Innovative green supercritical fluid chromatography development for the determination of polar compounds","volume":"1256","author":"Dispas","year":"2012","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2019.04.049_bib0080","unstructured":"Guideline, ICH Harmonised Tripartite - Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland. https:\/\/www.ich.org\/products\/guidelines.html."},{"key":"10.1016\/j.jpba.2019.04.049_bib0085","article-title":"Stimuli article: analytical target profile (ATP): structure and application throughout the analytical lifecycle","volume":"42","author":"Barnett","year":"2016","journal-title":"Pharmacopeial Forum"},{"key":"10.1016\/j.jpba.2019.04.049_bib0090","unstructured":"European Pharmacopoeia. 9th edition. Strasbourg: Council of Europe."},{"key":"10.1016\/j.jpba.2019.04.049_bib0095","volume":"vol 2","year":"2017"},{"key":"10.1016\/j.jpba.2019.04.049_bib0100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/15287394.2018.1460782","article-title":"Risk assessment of N-nitrosodiethylamine (NDEA) and N-nitrosodiethanolamine (NDELA) in cosmetics","volume":"81","author":"Lim","year":"2018","journal-title":"J Toxicol Environ Health A"},{"key":"10.1016\/j.jpba.2019.04.049_bib0105","first-page":"74","article-title":"New LC-MS\/MS method for the determination of eight nitrosamines in drinking water","volume":"17","author":"Galaon","year":"2016","journal-title":"J Environ Prot Ecol"},{"key":"10.1016\/j.jpba.2019.04.049_bib0110","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1021\/es5001352","article-title":"Detection and occurrence of N-Nitrosamines in archived biosolids from the targeted national sewage sludge survey of the U.S. Environmental protection agency","volume":"48","author":"Venkatesan","year":"2014","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.jpba.2019.04.049_bib0115","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1080\/19440049.2010.508184","article-title":"Liquid chromatography-tandem mass spectrometry determination of N-nitrosamines released from rubber or elastomer teats and soothers","volume":"27","author":"Sung","year":"2010","journal-title":"Food Addit. Contam. Part A"},{"key":"10.1016\/j.jpba.2019.04.049_bib0120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhazmat.2016.02.048","article-title":"Elevated urinary levels of carcinogenic N-nitrosamines in patients with urinary tract infections measured by isotope dilution online SPE LC\u2013MS\/MS","volume":"310","author":"Hu","year":"2016","journal-title":"J. Hazard. Mater."},{"key":"10.1016\/j.jpba.2019.04.049_bib0125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.chroma.2018.09.044","article-title":"Structure assisted impurity profiling for rapid method development in liquid chromatography","volume":"1577","author":"Schmidtsdorff","year":"2018","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2019.04.049_bib0130","series-title":"Update on the Review of CEP Applications for sartans.EDQM","author":"RIS.World Online","year":"2018"},{"key":"10.1016\/j.jpba.2019.04.049_bib0135","series-title":"Valsartan - Monograph Number: 02423. EDQM","author":"EDQM Knowledge Database","year":"2018"},{"key":"10.1016\/j.jpba.2019.04.049_bib0140","series-title":"Laboratory Analysis of Valsartan Products","author":"U.S. Food & Drug Administration","year":"2019"},{"key":"10.1016\/j.jpba.2019.04.049_bib0145","series-title":"Update on Detection of Nitrosamines in Valsartan and Validated Testing Method","author":"European network of OMCLs","year":"2018"},{"key":"10.1016\/j.jpba.2019.04.049_bib0150","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jpba.2018.11.010","article-title":"NDMA impurity in valsartan and other pharmaceutical products: analytical methods for the determination of N-nitrosamines","volume":"164","author":"Parr","year":"2019","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518328723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518328723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T16:54:50Z","timestamp":1564160090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708518328723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":30,"alternative-id":["S0731708518328723"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.04.049","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.04.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}